Sign inSign up
MicroRNAs analysis of patient-derived iPSCs as molecular therapy for ALS thumbnail
Pause
Mute
Subtitles not available
Playback speed
0.25
0.5
0.75
1
1.25
1.5
1.75
2
Full screen

MicroRNAs analysis of patient-derived iPSCs as molecular therapy for ALS

Published on Jul 21, 2017909 Views

Monica Nizzardo

Amyotrophic lateral sclerosis (ALS) is a fatal disorder characterized by progressive degeneration of motor neurons (MNs). The mechanisms underlying the disease and specific proteins involved are alm

ENCALS 2017 - Ljubljana

Related categories

MedicineNeuroscience

Chapter list

MicroRNAs analysis of patient-derived iPSCs and MNs as molecular therapy for ALS00:00
MicroRNAs (miRNAs)00:18
miRNA and ALS - 100:56
miRNA and ALS - 201:47
smallRNALS project02:00
iPSCs reprogramming03:07
Motor neurons (MNs) differentiation03:37
miRNAs expression analysis04:05
Taqman array miRNA cards04:40
miRNA cards on iPSCs - 105:03
miRNA cards on iPSCs - 205:12
miRNA cards on iPSCs - 305:45
miRNA cards on iPSCs - 405:47
miRNA cards on iPSC-derived MNs 05:56
Extracellular vesicles (EVs) miRNAs06:48
EVs and miRNAs isolation07:47
miRNA cards on iPSC-EVs - 108:22
miRNA cards on iPSC-EVs - 208:46
miRNA cards on iPSC-EVs - 3 08:47
miRNA cards on MNs-EVs 08:51
Bioinformatic analysis09:04
miR-129-5p is upregulated in ALS09:47
Next steps10:56
Acknowledgments12:11